PECULIARITIES OF DIAGNOSTICS AND COURSE OF UTERINE CERVICAL CANCER AMONG HIV-INFECTED WOMEN
1Department of Oncology, South Ural State Medical University, Chelyabinsk, Russian Federation
2Medical Centre Hospital of President’s Affairs Administration of the Republic of Kazakhstan, Astana, Republic of Kazakhstan
3Regional Oncological Dispensary of Akimat of the South Kazakhstan Region, Shymkent, Republic of Kazakhstan
Objective: To assess the clinical course of uterine cervical cancer (UCC) against the background of HIV infection and its complex diagnosis.
Methods: A retrospective analysis carried out to 847 outpatient cards of patients for the period 2016-2017. Of these, 17 were HIV-positive. Two groups were formed: group I – patients with UCC on the background of HIV, group II – patients with UCC without HIV. The mean age was 37.4±0.2 and 52.8±0.3 years, respectively. Stages of UCC in group I: IIB – 6 (35.5%), IIIA – 4 (23.5%), IIIB – 6 (35.5%), IVB – 1 (5.5%); in the II group: IB – 3 (15%), IIB – 10 (50%), IIIB – 6 (30%), IVB – 1 (5%). Distribution according to the histological structure in group I: squamous nonkeratinized cancer – 11 (68.75%), keratinizing – 1 (6.25%), adenocarcinoma – 4 (25%). In group II: squamous nonkeratinized cancer – 13 (65%), squamous keratinizing – 3 (15%), adenocarcinoma – 4 (2%). The groups were comparable in treatment methods: in both groups, chemoradiation therapy was used according to standard schemes.
Results: Indicators in the I group: lethality – 4 (23.5%), stabilization – 5 (23.5%), progression – 8 (53%); in the second group: lethality – 1 (5%), stabilization – 14 (70%), progression – 5 (25%).
Conclusions: UCC in the background of HIV infection occurs at an earlier age. The predominance of stage IIB disease and squamous nonkeratinized cancer in both groups was noted. Mortality within the first year, stabilization and progression in the I and II groups were 23.5%, 23.5%, 53% and 5%, 70%, 25%, respectively.
Keywords: Human immunodeficiency virus (HIV), uterine cervical cancer, lethality, stabilization, progressing.
- Booth CN, Bashleben C, Filomena CA, Means MM, Wasserman PG, Souers RJ, Henry MR. Monitoring and ordering practices for human papil-lomavirus in cervical cytology: findings from the College of American Pathologists Gynecologic Cytopathology Quality Consensus Conference working group 5. Arch Pathol Lab Med. 2013;137(2):214-9. Available from: http://dx.doi.org/10.5858/arpa.2012-0114-CP.
- Barillari G, Monini P, Sgadari C, Ensoli B. The impact of human papilloma viruses, matrix metallo-proteinases and HIV protease inhibitors on the on-set and progression of uterine cervix epithelial tumors: A review of preclin-ical and clinical studies. Int J Mol Sci. 2018;19(5):E1418. Available from: http://dx.doi.org/10.3390/ijms19051418.
- Segondy M, Ngou J, Kelly H, Omar T, Goumbri-Lompo O, Doutre S, et al. Diagnostic value of human papillomavirus (HPV) 16 and HPV 18 viral loads for the detection of high-grade cervical intraepithelial neoplasia (CIN2+) in a cohort of African women living with HIV. J Clin Virol. 2018;99-100:79-83. Available from: http://dx.doi.org/10.1016/j.jcv.2018.01.006.
- van Bogaert LJ. The impact of human immunodeficiency virus infection on cervical preinvasive and invasive neoplasia in South Africa. Ecancermedi-calscience. 2013;7:334. Available from: http://dx.doi.org/10.3332/ecancer.2013.334.
- Rafiev KhK, Nurov RM, Tursunov RA, Radzhabov ShV. Epidemiologicheskie osobennosti razvitiya VICH-infektsii v Tadzhikistane [The epidemic features of HIV infection in Tajikistan]. Vestnik Avitsenny [Avicenna Bulletin]. 2012;4:117-21.
- Miranda AE, Silveira MF, Travassos AG, Tenório T, Val ICC, Lannoy L, et al. High-risk papillomavirus infection among women living with human immunodeficiency virus: Brazilian multicentric study. J Med Virol. 2017; 89(12):2217-23. Available from: http://dx.doi.org/10.1002/jmv.24906.
- Sigfrid L, Murphy G, Haldane V, Chuah FLH, Ong SE, Cervero-Liceras F, et al. Integrating cervical cancer with HIV healthcare services: A systematic review. PloS One. 2017;12(7):e0181156. Available from: http://dx.doi.org/10.1371/journal.pone.0181156.
- Van Zummeren M, Kremer WW, Van Aardt MC, Breytenbach E, Richter KL, Rozendaal L, et al. Selection of women at risk for cervical cancer in an HIV-infected South African population. AIDS. 2017;31(14):1945-53. Available from: http://dx.doi.org/10.1097/QAD.0000000000001583.
- Ceccato Junior BP, Lopes AP, Nascimento LF, Novaes LM, Melo VH. Prevalence of cervical infection by human papillomavirus and cervical in-traepithelial neoplasia in HIV-positive and negative women. Rev Bras Ginecol Obstet. 2015; 37(4):178-85. Available from: http://dx.doi.org/10.1590/SO100-720320150005184.
- Tsoy VN, Rahmanov ER, Sharipov TM, Bukhoriev KM. Effektivnost i priverzhennost’ k terapii VICH-infektsii v Respublike Tadzhikistan [Effi-ciency and adherence to the therapy for HIV infection in the Republic of Tajikistan]. Vestnik Avitsenny [Avicenna Bulletin]. 2017;19(1):98-102. Available from: http://dx.doi.org/10.25005/2074-0581-2017-19-1-98-102.
- Firnhaber C, Swarts A, Goeieman B, Rakhombe N, Mulongo M, William-son AL, et al. Cryotherapy reduces progression of cervical intraepithelial neoplasia grade 1 in South African HIV-infected women: A randomized, controlled trial. J Acquir Immune Defic Syndr. 2017;76(5):532-8. Available from: http://dx.doi.org/10.1097/QAI.0000000000001539.
- Jaquet A, Horo A, Ekouevi DK, Toure B, Coffie PA, Effi B, et al. IeDEA West Africa Collaboration. Risk factors for cervical intraepithelial neo-plasia in HIV-infected women on antiretroviral treatment in Côte d'Ivoire, West Africa. PLoS One. 2014;9(3):e90625. Available from: http://dx.doi.org/10.1371/journal.pone.0090625.
- Badial RM, Dias MC, Stuqui B, Melli PPDS, Quintana SM, Bonfim CMD, et al. Detection and genotyping of human papillomavirus (HPV) in HIV-infected women and its relationship with HPV/HIV co-infection. Medicine (Baltimore). 2018;97(14):e9545. Available from: http://dx.doi.org/10.1097/MD.0000000000009545.
- Abdullahi A, Mustapha MI, David DA, Ayodeji OT. Human immunodefi-ciency virus seroprevalence in patients with invasive cervical cancer in Za-ria, North-Western Nigeria. Ann Afr Med. 2018;17(1):17-21. Available from: http://dx.doi.org/10.4103/aam.aam_37_17.
- Aho I, Kivelä P, Haukka J, Sutinen J, Heikinheimo O. Declining prevalence of cytological squamous intraepithelial lesions of the cervix among women living with well-controlled HIV – most women living with HIV do not need annual PAP smear screening. Acta Obstet Gynecol Scand. 2017;96(11):1330-7. Available from: http://dx.doi.org/10.1111/aogs.13207.
- Chen YC, Li CY, Liu HY, Lee NY, Ko WC, Ko NY. Effect of antiretroviral therapy on the incidence of cervical neoplasia among HIV-infected women: a population-based cohort study in Taiwan. AIDS. 2014;28(5):709-15. Available from: http://dx.doi.org/10.1097/QAD.0000000000000132.
- Silverberg MJ, Leyden WA, Chi A, Gregorich S, Huchko MJ, Kulasingam S, et al. Human immunodeficiency virus (HIV) – and non-HIV-associated immunosuppression and risk of cervical neoplasia. Obstet Gynecol. 2018;131(1):47-55. Available from: http://dx.doi.org/10.1097/AOG.0000000000002371.
- Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P, ART and HPV Review Group. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018; 5(1):e45-e58. Available from: http://dx.doi.org/10.1016/S2352-3018(17)30149-2.
- Heráclio SA, de Souza ASR, de Souza PRE, Katz L, Lima Junior SF, Amorim MMR. Cross-sectional study of anal intraepithelial lesions in women with cervical neoplasia without HIV. Int J Gynaecol Obstet. 2018;140(2):233-40. Available from: http://dx.doi.org/10.1002/ijgo.12367.
- Obiri-Yeboah D, Akakpo PK, Mutocheluh M, Adjei-Danso E, Allornuvor G, Amoako-Savkyi D, et al. Epidemiology of cervical human papilloma-virus (HPV) infection and squamous intraepithelial lesions (SIL) among a cohort of HIV-infected and uninfected Ghanaian women. BMC Cancer. 2017;17(1):688. Available from: http://dx.doi.org/10.1186/s12885-017-3682-x.
Bekhtereva Svetlana Aleksandrovna,
Candidate of Medical Sciences, Associate Professor of the Department of Oncology, South Ural State Medical University
Yaytsev Sergey Vasilievich,
Doctor of Medical Sciences, Full Professor, Head of the Department of Oncology, South Ural State Medical University
Akhetov Amir Amantaevich,
Doctor of Medical Sciences, Director, Medical Centre Hospital of President’s Affairs Administration of the Republic of Kazakhstan
Shanazarov Nasrulla Abdullaevich,
Doctor of Medical Sciences, Full Professor, Deputy Director for Science, Medical Centre Hospital of President’s Affairs Administration of the Republic of Kazakhstan
Asabaeva Rita Iskandarovna,
Postgraduate Student of the Department of Oncology, South Ural State Medical University; Doctor oncologist of the Regional Oncological Dispensary of the Akimat of the South Kazakhstan region
Address for correspondence:
Shanazarov Nasrulla Abdullaevich
Doctor of Medical Sciences, Professor, Deputy Director for Science of the Medical Centre Hospital of President’s Affairs Administration of the Republic of Kazakhstan
010000, Republic of Kazakhstan, Astana, str. E495, № 2
Tel.: (+7) 717 2708082
Materials on the topic:
- COMBINED TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH PERSONALIZED PRESCRIPTION OF ADJUVANT CHEMOTHERAPY
- MULTIMODAL APPROACH TO THE TREATMENT OF ESOPHAGEAL CANCER
- ETHNIC PECULIARITIES OF DISTRIBUTION OF ACUTE MYELOBLASTIC LEUKAEMIA IN CHILDREN’S POPULATION IN KYRGYZSTAN
- INDICATORS OF ANTICOAGULATIVE ACTIVITY OF VASCULAR WALL DEPENDING ON STAGE OF BREAST CANCER
- EMERGENCY SURGERY TO ONCOLOGICAL PATIENTS
- PALLIATIVE-CURATIVE SURGICAL INTERVENTIONS IN GASTRIC CANCER PATIENTS WITH LIVER METASTASES
- CHANGE OF EPIDEMIOLOGICAL SITUATION OF COLORECTAL CANCER IN KAZAKHSTAN AFTER INTRODUCTION OF SCREENING
- MICRONUCLEAR TEST OF THE BUCCAL EPITHELIUM AS THE SCREENING METHOD IN ONCOLOGY
- IMMUNITY SYSTEM AFTER EXTENDED SURGERIES IN PATIENTS WITH LOCALLY ADVANCED STOMACH CANCER